Comparative effectiveness of aggressive versus nonaggressive treatment among men with early‐stage prostate cancer and differing comorbid disease burdens at diagnosis

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer

• Publication date

  2014-08-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cncr.28757PMID 24824511
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of Age, Tumor Risk, and Comorbidity on Competing Risks for Survival in a U.S. Population–Based Cohort of Men With Prostate Cancer

  2013cited by this paper
• Cancer statistics, 2013

  2013cited by this paper
• Radical prostatectomy versus observation for localized prostate cancer.

  2012cited by this paper
• Comorbidity and competing risks for mortality in men with prostate cancer

  2011cited by this paper
• Overtreatment of men with low‐risk prostate cancer and significant comorbidity

  2011cited by this paper
• Impact of comorbidity on survival among men with localized prostate cancer.

  2011cited by this paper
• EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

  2011cited by this paper
• Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden.

  2011cited by this paper
• Overtreatment of men with low‐risk prostate cancer and significant comorbidity

  2011cited by this paper
• NCCN clinical practice guidelines in oncology: prostate cancer.

  2010cited by this paper
• Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data.

  2010cited by this paper
• Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer.

  2009cited by this paper
• National Institute of Diabetes and Digestive and Kidney Diseases

  2008cited by this paper
• Quality of life and satisfaction with outcome among prostate-cancer survivors.

  2008cited by this paper
• Quality of life and satisfaction with outcome among prostate-cancer survivors.

  2008cited by this paper
• Guideline for the management of clinically localized prostate cancer: 2007 update.

  2007cited by this paper
• Prostate cancer. Clinical practice guidelines in oncology.

  2007cited by this paper
• Data Sources for Measuring Comorbidity: A Comparison of Hospital Records and Medicare Claims for Cancer Patients

  2006cited by this paper
• Radical prostatectomy versus watchful waiting in early prostate cancer.

  2005cited by this paper
• Radical prostatectomy versus watchful waiting in early prostate cancer.

  2005cited by this paper
• Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities.

  2004cited by this paper
• Biochemical Outcome After Radical Prostatectomy , External Beam Radiation Therapy , or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer

  2000cited by this paper
• Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study.

  1999cited by this paper
• A Proportional Hazards Model for the Subdistribution of a Competing Risk

  1999cited by this paper
• Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

  1998cited by this paper
• Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

  1992cited by this paper
• Cancer statistics

  1989cited by this paper
• A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

  1987cited by this paper

• Physician Preferences Regarding Integration of Life Expectancy in Prostate Cancer Management.

  2026cites this paper
• Leveraging Machine Learning Models to Explore Disparities in Prostate Cancer Diagnosis, Treatment, and Survival

  2025cites this paper
• Patient preferences for life expectancy cutoffs for aggressive treatment in clinically localized prostate cancer.

  2024cites this paper
• Survival Outcomes for Men over 80 Years Undergoing Transrectal Ultrasound-Guided Prostate Biopsy: A Prospective Analysis

  2024cites this paper
• Association between urology practice use of multiparametric MRI and genomic testing and treatment of men with newly diagnosed prostate cancer.

  2023cites this paper
• The impact of life expectancy on cost-effectiveness of treatment options for clinically localized prostate cancer.

  2023cites this paper
• Urologist practice divestment from radiation vault ownership and treatment patterns for prostate cancer

  2023cites this paper
• Variation in Communication of Competing Risks of Mortality in Prostate Cancer Treatment Consultations

  2022cites this paper
• Patient Preferences for Communication of Life Expectancy in Prostate Cancer Treatment Consultations.

  2021cites this paper
• External Validation of the Prostate Cancer Specific Comorbidity Index, A Claims Based Tool for the Prediction of Life Expectancy in Men with Prostate Cancer.

  2019cites this paper
• Patterns and Prediction of Competing Causes of Mortality in Older Adults Diagnosed with Indolent Non-Hodgkin Lymphoma

  2017cites this paper
• More Judicious Use of Expectant Management for Localized Prostate Cancer during the Last 2 Decades

  2017cites this paper
• Comparative effectiveness of prostate cancer treatments for patient-centered outcomes

  2017cites this paper
• Outcomes of patients older than 75 years with non-metastatic prostate cancer

  2017cites this paper
• Limitations of the National Comprehensive Cancer Network® (NCCN®) Guidelines for Prediction of Limited Life Expectancy in Men with Prostate Cancer

  2017cites this paper
• Age Bias in Time From Diagnosis Comparisons of Prostate Cancer Treatment

  2016cites this paper
• Author Reply.

  2016cites this paper
• Comorbid Disease Burden is Independently Associated with Higher Risk Disease at Prostatectomy in Patients Eligible for Active Surveillance.

  2016cites this paper
• Questioning the 10-year Life Expectancy Rule for High-grade Prostate Cancer: Comparative Effectiveness of Aggressive vs Nonaggressive Treatment of High-grade Disease in Older Men With Differing Comorbid Disease Burdens.

  2016cites this paper
• The Relationship between Intolerance of Uncertainty and Anxiety in Men on Active Surveillance for Prostate Cancer.

  2016cites this paper
• Integrated prostate cancer centers might cause an overutilization of radiotherapy for low-risk prostate cancer: A comparison of treatment trends in the United States and Germany from 2004 to 2011.

  2015cites this paper
• The Importance of Accurate Life Expectancy Prediction in Men with Prostate Cancer.

  2015cites this paper
• An Age Adjusted Comorbidity Index to Predict Long-Term, Other Cause Mortality in Men with Prostate Cancer.

  2015cites this paper
• Age-adjusted Charlson comorbidity index is a significant prognostic factor for long-term survival of patients with high-risk prostate cancer after radical prostatectomy: a Bayesian model averaging approach

  2015cites this paper
• Prediction of long-term other-cause mortality in men with early-stage prostate cancer: results from the Prostate Cancer Outcomes Study.

  2015cites this paper
• Life Expectancy and Variation in Treatment for Early Stage Kidney Cancer.

  2015cites this paper
• Charlson score and competing mortality

  2014cites this paper
• In‐bag morcellation for presumed myoma retrieval at laparoscopy

  2014cites this paper
• Reply to Charlson score and competing mortality

  2014cites this paper